Needham analyst Michael Matson has reiterated their bullish stance on ESTA stock, giving a Buy rating on February 19.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Matson has given his Buy rating due to a combination of factors, including Establishment Labs’ strong revenue momentum and profitability improvement. The company delivered fourth‑quarter 2025 sales and adjusted EBITDA that exceeded market expectations, with overall revenue growth accelerating and U.S. demand showing particularly robust sequential gains.
He also points to expanding gross and adjusted EBITDA margins as evidence of improving operating leverage and a strengthening business model. In addition, Matson highlights management changes that bring experienced financial leadership, and he views ESTA as a differentiated small‑cap med‑tech growth story, supporting both his Buy recommendation and a higher price target based on 2027 revenue potential.
According to TipRanks, Matson is a 2-star analyst with an average return of 0.6% and a 43.98% success rate. Matson covers the Healthcare sector, focusing on stocks such as Masimo, TransMedics Group, and Atricure.
In another report released on February 19, TD Cowen also maintained a Buy rating on the stock with a $88.00 price target.